Skip to search formSkip to main contentSkip to account menu

Remoxipride

Known as: (S)-3-Bromo-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide, Remoxipridum, Remoxipride [Chemical/Ingredient] 
An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.
National Institutes of Health

Related topics

Related topics

16 relations

Broader (2)

Antipsychotic AgentsDopamine Antagonists

Narrower (6)

FLA 908FLA-731NCQ 344NCQ 436
In BloodRemoxipride Hydrochlorideagonistsanalogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Effect of lipophilicity of substituted benzamides on the dopaminergic effects in vivo and in vitro.
The antidopaminergic potencies of some new substituted benzamides related to remoxipride have been studied in the rat using in… 
2004
2004
Supersensitivity and clozapine withdrawal
The paper from Ekblom et al. (1984) and a report by Perenyi et al. (1985) on rapid relapse in schizophrenia after abrupt… 
1997
1997
Adverse drug reaction of the month--a new series.
This issue of the Postgraduate Medical Journal sees the launch of a new series of articles, Adverse drug reaction of the month… 
1996
1996
[Difference in prolaction response of schizophrenic patients to equivalent doses of haloperidol, remoxipride and sulpiride].
Clinically, most of the schizophrenics usually are treated with neuroleptics. This kind of medicine increases the prolactin level… 
Review
1996
Review
1996
Adverse Effects of Antipsychotic Agents
SummaryAlthough antipsychotic drugs are effective in treating the so-called positive features of schizophrenia, between one… 
1992
1992
Insomnia in Psychiatric Patients - the Hypnotic Effect and Withdrawal Problems of Zopiclone and Temazepam
1992
1992
PATIENT EXPERIENCE WITH REMOXIPRIDE ‐ RESULTS CONVEYED BY PATIENTS IN GROUP MEETINGS AND INDIVIDUAL INTERVIEWS
1987
1987
Remoxipride, a novel atypical neuroleptic, in the treatment of schizophrenia.
1986
1986
An early phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity.
1984
1984
REMOXIPRIDE - A POTENTIAL ANTIPSYCHOTIC DRUG WITH SELECTIVE DOPAMINE D2 RECEPTOR PROPERTIES
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)